SEC Speeds Up Nasdaq Bitcoin Index Options for Wall Street Traders
Published Date: 8/3/2026
Notice
Summary
The SEC is reviewing Nasdaq PHLX's plan to start trading options based on the Nasdaq Bitcoin Index. This change affects investors interested in Bitcoin and could bring new trading opportunities soon. The SEC is speeding up the approval process and asking for public feedback before making a final decision.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
Nasdaq Bitcoin Options Approval Stayed
On May 22, 2026 the Division had approved Nasdaq PHLX’s plan to list and trade Nasdaq Bitcoin Index options, but the Commission granted CME Group’s petition for review on July 29, 2026 and ordered that the Approval Order is stayed. Any party or person may file a written statement in support of or opposition to the Approval Order on or before August 24, 2026; trading under the Approval Order remains paused until the Commission decides otherwise.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-12163, The Trade-Through Rule and Locked and Crossed Markets Provisions of Regulation NMS
The SEC wants to scrap some old rules that stop stocks from being traded at worse prices and prevent confusing market quotes. This change affects stock traders and exchanges, aiming to simplify trading and possibly speed things up. If you want to share your thoughts, you’ve got until August 17, 2026, so don’t miss out!
2026-10373, Registered Offering Reform
The SEC wants to make it easier and cheaper for more companies to sell their stocks and bonds to the public. They’re opening up special forms and benefits to more businesses, updating rules to be more modern, and cutting red tape by overriding some state rules. If you’re a company planning to raise money, these changes could speed things up and save you money, with feedback due by July 27, 2026.
2026-10222, Enhancement of Emerging Growth Company Accommodations and Simplification of Filer Status for Reporting Companies
The SEC is making it easier for companies that report their finances by simplifying their categories into just two groups: big and small filers. Smaller companies, including emerging growth ones, will get more time to file reports and enjoy simpler rules, while big companies keep stricter standards. These changes aim to save time and money, with feedback open until July 20, 2026.
2026-07651, Concept Release on Consolidated Audit Trail and Other Audit Trails and Data Sources
The SEC wants your thoughts on how it tracks stock market trades using the Consolidated Audit Trail and other data tools. They’re thinking about updating rules to keep up with new tech, privacy, and security needs, and to make sure the system is fair and cost-effective. If you’re involved in the stock market or data tracking, speak up by June 22, 2026!
2026-15616, Self-Regulatory Organizations; The Nasdaq Stock Market LLC; Notice of Filing and Immediate Effectiveness of Proposed Rule Change To Amend Nasdaq General 4, Rule 1210
Nasdaq is speeding up how soon people can retake certain FINRA exams by shortening the waiting times. This change helps traders and professionals get back on track faster without extra costs or delays. The new rule is effective immediately, making it easier for those involved in the stock market to stay qualified and active.
2026-15604, Baillie Giffords Funds, et al.
Previous / Next Documents
Previous: 2026-15613, Assessing Adhesion With Transdermal and Topical Delivery Systems for ANDAs; Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry titled "Assessing Adhesion With Transdermal and Topical Delivery Systems for ANDAs." This guidance provides recommendations for the design and conduct of studies evaluating the adhesion performance of a transdermal or topical delivery system (collectively referred to as TDS). Depending on the objectives of a generic TDS product development program, applicants may choose to evaluate TDS adhesion in studies performed to evaluate TDS adhesion only, or in studies performed with a combined purpose (e.g., for the simultaneous evaluation of adhesion and bioequivalence (BE) with pharmacokinetic (PK) endpoints). The recommendations in this guidance relate to studies submitted in support of an abbreviated new drug application (ANDA). The guidance replaces the draft guidance (Revision 2) "Assessing Adhesion With Transdermal and Topical Delivery Systems for ANDAs," issued on April 13, 2023.
Next: 2026-15616, Self-Regulatory Organizations; The Nasdaq Stock Market LLC; Notice of Filing and Immediate Effectiveness of Proposed Rule Change To Amend Nasdaq General 4, Rule 1210
Nasdaq is speeding up how soon people can retake certain FINRA exams by shortening the waiting times. This change helps traders and professionals get back on track faster without extra costs or delays. The new rule is effective immediately, making it easier for those involved in the stock market to stay qualified and active.